197 related articles for article (PubMed ID: 20361986)
1. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.
Ferguson MC; Nayyar T; Deutch AY; Ansah TA
Neuropharmacology; 2010; 59(1-2):31-6. PubMed ID: 20361986
[TBL] [Abstract][Full Text] [Related]
2. Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.
Ferguson MC; Nayyar T; Ansah TA
Neurochem Int; 2014 May; 71():36-46. PubMed ID: 24704796
[TBL] [Abstract][Full Text] [Related]
3. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
4. Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Di Paolo T
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():27-38. PubMed ID: 25046277
[TBL] [Abstract][Full Text] [Related]
5. The 5-HT(2A) Receptor Antagonist M100907 Produces Antiparkinsonian Effects and Decreases Striatal Glutamate.
Ansah TA; Ferguson MC; Nayyar T
Front Syst Neurosci; 2011; 5():48. PubMed ID: 21716656
[TBL] [Abstract][Full Text] [Related]
6. Combined 5-HT
Kwan C; Frouni I; Nuara SG; Belliveau S; Kang W; Hamadjida A; Bédard D; Beaudry F; Panisset M; Gourdon JC; Huot P
Neuropharmacology; 2021 Mar; 186():108465. PubMed ID: 33485945
[TBL] [Abstract][Full Text] [Related]
7. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
8. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
9. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
[TBL] [Abstract][Full Text] [Related]
10. Effects of acute treatments with the serotonin 2A antagonist M100907 alone or in combination with the serotonin 2C agonist WAY163909 on methamphetamine self-administration in rhesus monkeys.
Odabas-Geldiay M; Shields H; Berro LF; Rice KC; Howell LL
Drug Alcohol Depend; 2019 Jan; 194():252-256. PubMed ID: 30469095
[TBL] [Abstract][Full Text] [Related]
11. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).
Martin P; Waters N; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1997; 104(4-5):561-4. PubMed ID: 9295186
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
13. Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.
Cunningham KA; Anastasio NC; Fox RG; Stutz SJ; Bubar MJ; Swinford SE; Watson CS; Gilbertson SR; Rice KC; Rosenzweig-Lipson S; Moeller FG
ACS Chem Neurosci; 2013 Jan; 4(1):110-21. PubMed ID: 23336050
[TBL] [Abstract][Full Text] [Related]
14. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.
Taylor JL; Bishop C; Ullrich T; Rice KC; Walker PD
Neuropharmacology; 2006 May; 50(6):761-8. PubMed ID: 16434065
[TBL] [Abstract][Full Text] [Related]
15. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
16. The highly selective 5-HT
Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
[TBL] [Abstract][Full Text] [Related]
17. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
[TBL] [Abstract][Full Text] [Related]
18. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
Huot P; Johnston TH; Winkelmolen L; Fox SH; Brotchie JM
Neurobiol Aging; 2012 Jan; 33(1):194.e5-15. PubMed ID: 20561716
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding.
Fletcher PJ; Grottick AJ; Higgins GA
Neuropsychopharmacology; 2002 Oct; 27(4):576-86. PubMed ID: 12377394
[TBL] [Abstract][Full Text] [Related]
20. Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.
Cote SR; Kuzhikandathil EV
Neurosci Lett; 2015 Jan; 585():33-7. PubMed ID: 25445374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
